Synvista Therapeutics Announces Initiation Of Phase 2 Study With Alagebrium For Chronic Heart Failure

Synvista Therapeutics, Inc. (AMEX: SYI) announced , dosing of the first patient in BENEFICIAL, a 100-patient Phase 2 clinical trial of alagebrium (ALT-711), a novel compound designed to act as an Advanced Glycation End-product (AGE)-cross-link breaker, in patients with chronic heart failure (CHF). [click link for full article]

More: continued here

Comments are closed.



Free prescriptions rx - : Free prescriptions rx
Get Rx Pharmacy - : Get Rx Pharmacy
Online Antibiotics - Buy Drugs: Online Antibiotics
Online RX Pharmacy - Buy Drugs: Online Rx pharmacy
Order Cheap Pills - Buy Drugs: Order Cheap Pills from online pharmacy.
Pills 2 Me - Order RX Pills for You: Just select the medicines you need, fill in our medical questionnaire, and submit your order.
Rx Drug Store Online - Drugstore: Rx drug store online
RX Pharmacy Online - Buy Drugs: RX Pharmacy Online
RX Pills Online - Buy Drugs: Rx pills online
Your Health Rx - : Your Health Rx
Online rx pharma - : Online rx pharma
Prescript aware - : Prescript aware
Privacy plus prescriptions - : Privacy plus prescriptions
Rx Meds Online - Rx Meds Online: Medical Rx online
Latest News...